Cancer Drug Encyclopedia
Approved oncology medications — what they treat, how they work and key safety information.
HER2-positive or HER2-low metastatic Breast Cancer, HER2-mutant Non-Small Cell Lung Cancer, and Gastric Adenocarcinoma.
Approved for use in oncology care according to FDA-approved indications.
First-line and adjuvant treatment of melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma, classical Hodgkin lymphoma, urothelial carcinoma, microsatellite instability-high (MSI-H) solid tumors, triple-negative breast cancer (TNBC), and cervical cancer.
Approved for use in oncology care according to FDA-approved indications.
HR-positive, HER2-negative advanced, metastatic, or high-risk early Breast Cancer.
HR-positive, HER2-negative advanced, metastatic, or high-risk early Breast Cancer.
BRAF V600E/K mutation-positive Melanoma, Non-Small Cell Lung Cancer, Anaplastic Thyroid Cancer, and Colorectal Cancer.
KRAS G12C-mutated Non-Small Cell Lung Cancer and advanced Colorectal Cancer.
Relapsed or refractory B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Mantle Cell Lymphoma, or Multiple Myeloma.
Multiple Myeloma and Myelodysplastic Syndromes.